Form 4: Xilio CMO Reports Equity Awards, RSU Vesting

Xilio Therapeutics' Chief Medical Officer, Katarina Luptakova, reported the vesting of restricted stock units and the grant and partial vesting of stock options.

Summary

• Katarina Luptakova, Chief Medical Officer of Xilio Therapeutics, Inc. (XLO), reported changes in her beneficial ownership.
• On January 1, 2026, 16,625 shares of common stock were acquired due to the vesting of Restricted Stock Units (RSUs).
• These RSUs were originally granted on January 1, 2024, and vest in four equal annual installments starting January 1, 2025.
• Following this transaction, Ms. Luptakova beneficially owns 33,250 shares of common stock directly.
• On December 31, 2025, 451,885 stock options were acquired, with an exercise price of $0.841 per share and an expiration date of October 7, 2035.
• These options, referred to as 'Tranche 3 Options,' were granted on October 8, 2025, by the Compensation Committee, subject to stockholder approval of the 2025 Stock Incentive Plan.
• Stockholders approved the 2025 Plan on November 21, 2025.
• A portion of these Tranche 3 Options met their performance criteria on December 31, 2025.
• The vested portion of Tranche 3 Options is tied to the percentage of Series B Warrants exercised or cancelled due to Xilio Therapeutics receiving Non-Dilutive Capital by December 31, 2025.
• These options will vest in three equal annual installments over a three-year period beginning December 31, 2025, contingent on Ms. Luptakova's continued service.

Sentiment

Score: 6

Explanation: The filing reports routine executive compensation events, including RSU vesting and option grants/vesting. The achievement of performance criteria for options, linked to non-dilutive capital, is a positive indicator. Overall, it's a neutral to slightly positive report reflecting ongoing operations and incentive alignment.

Positives

• The vesting of 16,625 Restricted Stock Units (RSUs) on January 1, 2026, represents a scheduled compensation event, increasing the Chief Medical Officer's direct equity ownership.
• The grant and partial vesting of 451,885 stock options on December 31, 2025, indicates continued incentive alignment between management and shareholders.
• The performance criteria for a portion of the Tranche 3 Options were met, suggesting the company achieved certain operational or financial milestones related to Non-Dilutive Capital by December 31, 2025.

Future Outlook

The vesting schedules for both the Restricted Stock Units (RSUs) and the stock options extend into future years, contingent on the Chief Medical Officer's continued service. The performance-based vesting of options tied to the receipt of Non-Dilutive Capital suggests future strategic financial activities for the company.

Industry Context

This Form 4 filing reflects routine executive compensation practices within the biotechnology or pharmaceutical industry, where equity awards like RSUs and stock options are common tools to attract, retain, and incentivize key personnel, aligning their interests with long-term shareholder value.

Corporate Governance

Stakeholder Impact

• Shareholders: The grant and vesting of equity awards can lead to potential future dilution if options are exercised or RSUs convert to shares, but also serves to align management's interests with long-term shareholder value.
• Employees (specifically the Chief Medical Officer): Represents a significant component of compensation, incentivizing continued service and performance.

Next Steps

• Continued vesting of the remaining Restricted Stock Units (RSUs) in equal annual installments.
• Continued vesting of the stock options in three equal annual installments over the three-year period beginning December 31, 2025, subject to continued service.

Key Dates

Recommendation

This Form 4 filing details routine executive compensation events, specifically the vesting of restricted stock units and the grant and partial vesting of stock options. While the achievement of performance criteria for options tied to non-dilutive capital is a positive operational note, these are standard compensation disclosures and do not typically provide new material information that would significantly alter an investment thesis or warrant a change in recommendation. The filing confirms ongoing incentive alignment and operational milestones but does not present new financial performance data or strategic shifts that would prompt a 'buy' or 'sell' recommendation.

Keywords

Xilio Therapeutics, XLO, Form 4, Insider Transaction, Stock Options, Restricted Stock Units, Equity Compensation, Chief Medical Officer, Vesting, Non-Dilutive Capital